Interferon-beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription

  • Keivan Basiri Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. AND Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Masood Etemadifar Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. AND Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Fatemeh Derakhshan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Fereshteh Ashtari Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. AND Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Vahid Shaygannejad Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. AND Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Zahra Fatehi Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Amir Hadi Maghzi Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Farzad Fatehi Mail Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. AND Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran
Keywords:
Multiple Sclerosis, Pediatrics, Childhood, Interferons

Abstract

None of the approved immunomodulatory drugs in adults Multiple Sclerosis (MS) patients have been officially approved for the pediatric patients and are currently used off-label in this population. In this study, we evaluated the effectiveness and tolerability of intramuscular interferon beta1-a (Avonex®) and subcutaneously injected interferon beta1-b (Betaferon®) in children with definite relapsing-remitting MS (RRMS). Thirteen patients aged younger than 16, who were recently diagnosed with definite RRMS according to the McDonald's criteria, were enrolled in this study. Six patients were treated with Avonex® 30 μg, intramuscularly every week, and seven patients were treated with Betaferon® 250 μg, subcutaneously every other day. All patients were treated with adult doses; initially interferon-beta was prescribed with half dose, and it was increased to full adult dose steadily. Eleven girls and two boys, mean (SD) age of 14.7 (1.9) years, were studied. Following nine months of using interferon-beta, nine patients (69.2%) had no relapses and the remaining four, experienced only one relapse. The mean EDSS score was decreased significantly after the study period. The present study provides reasonable data for the use of interferon-beta in Pediatric MS due to lack of short-term complications and safety. Studies with larger sample size and longer follow up duration are required to shed light on the long term impact of the interferon-beta therapy in children.

References

Ozakbas S, Idiman E, Baklan B, Yulug B. Childhood and juvenile onset multiple sclerosis: clinical and paraclinicalfeatures. Brain Dev 2003;25(4):233-6.

Gadoth N. Multiple sclerosis in children. Brain Dev 2003;25(4):229-32.

Ruggieri M, Polizzi A, Pavone L, Grimaldi LM. Multiple sclerosis in children under 6 years of age. Neurology 1999;53(3):478-84.

Thomas T, Banwell B. Multiple sclerosis in children. Semin Neurol 2008;28(1):69-83.

Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, Pohl D, Freedman M, Schelensky L, Antonijevic I. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006;66(4):472-6.

Ghezzi A; Immunomodulatory Treatment of Early Onset MS (ITEMS) Group. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Cooperative Study. Neurol Sci 2005;26 Suppl 4:S183-6.

Pakdaman H, Fallah A, Sahraian MA, Pakdaman R, Meysamie A. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics 2006;37(4):257-60.

Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu MG, Martinelli V, Milanese C, Moiola L, Milani N, La Mantia L, Patti F, Pozzilli C, Trojano M, Comi G, Zaffaroni M; Immunomodulatory Treatment of Early-onset MS (ITEMS) Group. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci 2007;28(3):127-32.

Pohl D, Waubant E, Banwell B, Chabas D, Chitnis T, Weinstock-Guttman B, Tenembaum S; International Pediatric MS Study Group. Treatment of pediatric multiple sclerosis and variants. Neurology 2007;68(16 Suppl2):S54-65.

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58(6):840-6.

Ghezzi A. Childhood-juvenile multiple sclerosis: clinical characteristics and treatment. Expert Rev Neurother 2005;5(3):403-11.

Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D; University of British Columbia MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study. Neurology 2002;59(7):1006-10.

Coyle PK, Hartung HP. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult Scler 2002;8(1):2-9.

Mikaeloff Y, Moreau T, Debouverie M, Pelletier J, Lebrun C, Gout O, Pedespan JM, Van Hulle C, Vermersch P, Ponsot G. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr 2001;139(3):443-6.

How to Cite
1.
Basiri K, Etemadifar M, Derakhshan F, Ashtari F, Shaygannejad V, Fatehi Z, Hadi Maghzi A, Fatehi F. Interferon-beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription. Acta Med Iran. 50(2):97-100.
Section
Articles